Meeting
2022 ASCO Annual Meeting
Indirect assessment of tumor-infiltrating lymphocyte activity in serum for predicting outcome in patients with glioblastoma treated with immunotherapy in the recurrent setting.
Authors
Christina Jensen
Biomarkers & Research, Nordic Bioscience, Herlev, Denmark
Christina Jensen , Simone Bendix Maarup , Hans Skovgaard Poulsen , Benedikte Hasselbalch , Morten A. Karsdal , Inge Marie Svane , Ulrik Niels Lassen , Nicholas Willumsen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03890952
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2059)
DOI
10.1200/JCO.2022.40.16_suppl.2059
Abstract #
2059
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).
First Author: Rebecca L. Porter
Poster
2023 ASCO Annual Meeting
Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.
First Author: Yu Yao
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2022 ASCO Annual Meeting
Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.
First Author: Elio Adib